Scilex Holding Co

NASDAQ:SCLXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.

Contact Information

Headquarters

960 San Antonio RoadPALO ALTO, CA, United States 94303

Phone

650-516-4310

Fax

302-636-5454

Executives

Executive Chairman of the Board

Henry Ji

President, Chief Executive Officer, Director

Jaisim Shah

Chief Financial Officer, Senior Vice President, Company Secretary

Stephen Ma

Director

Jay Chun

Director

Annu Navani